Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELAB NASDAQ:ENVB NASDAQ:GRI NASDAQ:HEPA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELABPMGC$2.29-10.9%$2.26$1.95▼$756.00$3.53M0.13390,946 shs254,682 shsENVBEnveric Biosciences$1.23-8.2%$1.27$1.01▼$11.55$3.31M0.54777,634 shs1.06 million shsGRIGRI Bio$1.80-2.7%$1.42$1.10▼$43.69$4.62M-1.62133,134 shs184,859 shsHEPAHepion Pharmaceuticals$0.05-6.4%$0.10$0.04▼$56.00$528K1.691.31 million shs167,732 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELABPMGC-10.89%-0.43%+10.10%-11.24%-99.67%ENVBEnveric Biosciences-8.21%-4.65%+1.65%0.00%-84.87%GRIGRI Bio-2.70%+9.09%+38.46%+17.65%-93.77%HEPAHepion Pharmaceuticals-14.21%-19.50%-31.10%-85.92%-99.91%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELABPMGC0.5956 of 5 stars0.04.00.00.01.90.00.6ENVBEnveric Biosciences2.8507 of 5 stars3.52.00.00.04.40.01.3GRIGRI Bio3.006 of 5 stars3.54.00.00.03.00.01.3HEPAHepion Pharmaceuticals0.2548 of 5 stars0.03.00.00.01.10.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELABPMGC 0.00N/AN/AN/AENVBEnveric Biosciences 3.00Buy$10.00713.01% UpsideGRIGRI Bio 3.00Buy$22.001,122.22% UpsideHEPAHepion Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest HEPA, ENVB, ELAB, and GRI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025GRIGRI BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/27/2025GRIGRI BioAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $34.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELABPMGC$1.71M1.85N/AN/A$11.53 per share0.20ENVBEnveric BiosciencesN/AN/AN/AN/A$2.35 per shareN/AGRIGRI BioN/AN/AN/AN/A$7.68 per shareN/AHEPAHepion PharmaceuticalsN/AN/AN/AN/A$1.29 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELABPMGC-$6.25M-$433.87N/A∞N/AN/A-77.80%-59.17%8/13/2025 (Estimated)ENVBEnveric Biosciences-$9.57M-$38.38N/AN/AN/AN/A-250.28%-195.57%8/11/2025 (Estimated)GRIGRI Bio-$8.21M-$11.56N/AN/AN/AN/A-275.15%-168.22%8/12/2025 (Estimated)HEPAHepion Pharmaceuticals-$48.93M-$219.00N/A∞N/AN/A-812.56%-207.31%8/11/2025 (Estimated)Latest HEPA, ENVB, ELAB, and GRI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025GRIGRI Bio-$1.31N/AN/AN/AN/AN/A5/15/2025Q1 2025GRIGRI Bio-$4.08-$5.80-$1.72-$5.80N/AN/A5/14/2025Q1 2025ELABPMGCN/A-$2.90N/A-$2.95N/AN/A5/14/2025Q1 2025ENVBEnveric Biosciences-$3.45-$1.22+$2.23-$1.22N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELABPMGCN/AN/AN/AN/AN/AENVBEnveric BiosciencesN/AN/AN/AN/AN/AGRIGRI BioN/AN/AN/AN/AN/AHEPAHepion PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELABPMGCN/A8.978.97ENVBEnveric BiosciencesN/A4.084.08GRIGRI BioN/A1.411.41HEPAHepion PharmaceuticalsN/A1.301.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELABPMGC22.22%ENVBEnveric Biosciences13.82%GRIGRI Bio33.95%HEPAHepion Pharmaceuticals17.24%Insider OwnershipCompanyInsider OwnershipELABPMGC0.60%ENVBEnveric Biosciences3.20%GRIGRI Bio0.13%HEPAHepion Pharmaceuticals0.06%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELABPMGC181.38 million1.37 millionN/AENVBEnveric Biosciences202.47 million2.39 millionNot OptionableGRIGRI Bio12.50 million2.14 millionNot OptionableHEPAHepion Pharmaceuticals2010.93 million6.63 millionNo DataHEPA, ENVB, ELAB, and GRI HeadlinesRecent News About These CompaniesHepion Pharmaceuticals CFO John Brancaccio resigns effective MondayJuly 1, 2025 | investing.comHepion Pharmaceuticals Successfully Completes Application to the OTCQBJune 25, 2025 | globenewswire.comHEPA Hepion Pharmaceuticals, Inc.CJune 22, 2025 | seekingalpha.comHepion names new interim CEO, shifts to diagnostic innovationJune 18, 2025 | njbiz.comNHepion Pharmaceuticals Appoints Kaouthar Lbiati As Interim CEOJune 17, 2025 | nasdaq.comHepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive OfficerJune 16, 2025 | manilatimes.netMHepion Pharmaceuticals reports annual meeting resultsJune 14, 2025 | investing.comHepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Announces Receipt of Delisting Notification from NasdaqMay 13, 2025 | finanznachrichten.deHepion Pharma Stock Draws Bullish Retail Bets Despite Nasdaq Delisting Notice: 'Could Get Interesting'May 12, 2025 | msn.comHepion Pharmaceuticals Announces Receipt of Delisting Notification from NasdaqMay 12, 2025 | globenewswire.comHepion Pharmaceuticals Enters Binding LOI with New Day Diagnostics for In-Licensing of CE-Marked Diagnostic TestsMay 9, 2025 | nasdaq.comHepion Partners With New Day Diagnostics To Commercialize Diagnostic TestsMay 9, 2025 | nasdaq.comHepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCCMay 7, 2025 | globenewswire.comHepion Pharmaceuticals faces potential Nasdaq delistingMarch 22, 2025 | investing.comHepion Pharmaceuticals enacts reverse stock splitMarch 21, 2025 | investing.comHepion Pharmaceuticals trading halted, news pendingMarch 18, 2025 | markets.businessinsider.comHepion Pharmaceuticals announces 1-for-50 reverse stock splitMarch 14, 2025 | markets.businessinsider.comHepion Pharmaceuticals Announces Reverse Stock SplitMarch 14, 2025 | globenewswire.comHepion Pharmaceuticals Inc’s Stock Drama: Could This Be a Game-Changer for HEPA Investors?February 4, 2025 | bovnews.comBHepion Pharmaceuticals Inc (HEPA) Stock: More Resilient Than It AppearsJanuary 28, 2025 | bovnews.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHEPA, ENVB, ELAB, and GRI Company DescriptionsPMGC NASDAQ:ELAB$2.29 -0.28 (-10.89%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$2.26 -0.04 (-1.53%) As of 07/15/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.Enveric Biosciences NASDAQ:ENVB$1.23 -0.11 (-8.21%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$1.22 -0.01 (-0.81%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.GRI Bio NASDAQ:GRI$1.80 -0.05 (-2.70%) As of 07/15/2025 04:00 PM EasternGRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.Hepion Pharmaceuticals NASDAQ:HEPA$0.05 0.00 (-6.40%) As of 07/15/2025 03:53 PM EasternHepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Fastenal Surges After Earnings Beat, Tariff Risks Loom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
